Preparation, Characterization and Reactivity of a Bis-hypochlorite Adduct of a Chiral Manganese(IV) Salen Complex
作者:Ikuko Araki、Kaoru Fukui、Hiroshi Fujii
DOI:10.1021/acs.inorgchem.7b02661
日期:2018.2.19
2-tBu is much lower than that reported for the catalytic reactions by Jacobsen’s catalyst. The low enantioselectivity is consistent with a planar conformation of the salen ligand, which is suggested by circular dichroism spectroscopy. This study suggests that 2-tBu is not a reactive intermediate of Jacobsen’s enantioselectiveepoxidation catalysis.
具有多种手性(R,R)-环己烷-1,2-二胺键(2 - t Bu)的锰(IV)赛伦锰配合物的双次氯酸盐加合物已成功制备并通过各种光谱方法表征。2- t Bu与各种有机底物的反应表明,2- t Bu能够进行硫氧化,环氧化,氯化和夺氢反应。然而,2- t Bu对环氧化反应的对映选择性远远低于雅各布森(Jacobsen)催化剂进行催化反应的报道。低对映选择性与salen配体的平面构象一致,这由圆二色性光谱法表明。这项研究表明2- t Bu不是雅各布森对映选择性环氧化催化反应的中间体。
Sodium hypochlorite pentahydrate (NaOCl·5H2O) crystals; An effective re-oxidant for TEMPO oxidation
presence or absence of phase-transfer catalysts. The pentahydrate crystals alone (without nitroxyl radicals) demonstrate a powerful oxidizing ability, converting secondary alcohols to the corresponding ketones. In the presence of TEMPO (2,2,6,6-tetramethylpiperidine 1-oxyl) or 1-Me-AZADO (1-methyl-2-azaadamantane N-oxy radical), sterically hindered secondary alcohols are oxidized without pH adjustment
NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
申请人:Pelletier Jeffrey Claude
公开号:US20090054392A1
公开(公告)日:2009-02-26
The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.
Compounds Which Selectively Modulate The CB2 Receptor
申请人:BARTOLOZZI Alessandra
公开号:US20100081644A1
公开(公告)日:2010-04-01
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor
申请人:BARTOLOZZI Alessandra
公开号:US20110312932A1
公开(公告)日:2011-12-22
Compounds of formula (I)
are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.